Oral D Alpan

US Patent:

7867974, Jan 11, 2011

Filed:

Apr 12, 2007

Appl. No.:

11/734489

Inventors:

Oral Alpan - Rockville MD, US
Tirumalai Kamala - Rockville MD, US
Polly Matzinger - Bethesda MD, US
William Hugold Velander - Blacksburg VA, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC
Virginia Tech Intellectual Properties, Inc. - Blacksburg VA

International Classification:

A61K 38/00

US Classification:

514 12, 530383

Abstract:

Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.

US Patent:

20040209829, Oct 21, 2004

Filed:

Feb 2, 2004

Appl. No.:

10/485696

Inventors:

Oral Alpan - Rockville MD, US
Polly Matzinger - Bethesda MD, US
William Velander - Blacksburg VA, US

International Classification:

A61K038/36
A61K048/00

US Classification:

514/044000, 514/012000

Abstract:

Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.

US Patent:

20220187316, Jun 16, 2022

Filed:

Mar 17, 2020

Appl. No.:

17/440620

Inventors:

- Fairfax VA, US
Oral Alpan - Fairfax VA, US

International Classification:

G01N 33/68
G01N 33/88
A61K 31/519

Abstract:

T cell surface marker, CRTH2, is a target for treating Postural Orthostatic Tachycardia Syndrome, a hemodynamic abnormality. Targeting CRTH2 permits control of disease symptoms in POTS, for which no FDA approved treatment is currently available. Cell surface expression on certain T cell subsets characterizes the syndrome. Cell surface expression can be conveniently determined in plasma samples using flow cytometry.

US Patent:

20230042509, Feb 9, 2023

Filed:

Jun 22, 2022

Appl. No.:

17/847061

Inventors:

- McLean VA, US
Oral ALPAN - Fairfax VA, US

Assignee:

Amerimmune LLC - McLean VA

International Classification:

A61K 31/551
A61K 31/197
A61K 31/4025
A61K 31/573
A61K 31/675
A61K 39/395
A61P 31/14

Abstract:

Up-regulation of caspase has been found in COVID-19 patients, and also occurs in patients suffering from diabetes, hypertension, metabolic syndrome, and other conditions. Such up-regulation can be responsible for poor clinical outcomes in patients having such diseases or disorders, as such up-regulation leads to a process called pyroptosis: death and malfunction of immune system cells, particularly of certain types of lymphocytes. An inhibitor of caspase such as a caspase 1 inhibitor, or “pan-caspase” inhibitor (i.e., an inhibitor of multiple caspase types including caspase-1), can be used to treat COVID-19 patients or individuals at risk of infection, by limiting the malfunction of the immune system. A caspase-1 or pan-caspase inhibitor is advantageously administered before or very early in the course of infection by a positive-sense, single-stranded RNA virus such as SARS-CoV, MERS-CoV, or SARS-Cov-2.

US Patent:

20160271112, Sep 22, 2016

Filed:

Oct 27, 2014

Appl. No.:

15/031991

Inventors:

Oral ALPAN - Fairfax VA, US
Benjamin I. ENAV - Burke VA, US

International Classification:

A61K 31/429
A61K 45/06
A61K 9/00

Abstract:

Methods for treating or relieving at least one symptom of urticarial disorders including chronic idiopathic urticaria, angioedema, and anaphylaxis, or a combination of these disorders in a mammal, including humans. The method comprises administering to the mammal a therapeutically effective amount of pramipexole, dexpramipexole or pharmaceutically acceptable salts thereof.